Viatris divested its biosimilars portfolio to Biocon Biologics and announced agreements to divest its OTC business, women's healthcare business, and API business in India. These actions are part of a strategic vision to simplify the business and accelerate debt paydown.

Viatris completed the acquisition of Oyster Point for $427.4 million, signaling a strategic focus on ophthalmology. This acquisition is intended to create a leading global ophthalmology franchise.

New product sales, including lenalidomide and Breyna™ in the U.S., contributed $451.3 million to net sales. This indicates a focus on innovation and new product development to offset declines in existing products.

The 2020 restructuring program is substantially complete, with approximately $1.4 billion in pre-tax charges incurred. This program is designed to optimize operations and reduce costs.

The company is focused on reducing debt and returning capital to shareholders. This is evidenced by the share repurchase program and the continued payment of dividends.

Management concluded that the Company maintained effective internal control over financial reporting as of December 31, 2023. This provides assurance in the reliability of financial reporting.

The 10K highlights risks associated with pending divestitures, including potential delays, failure to realize transaction values, and disruptions to business relationships. These divestitures are a key part of Viatris' strategy.

The 10K acknowledges ongoing pressure on pricing and reimbursements due to pricing controls, social pressure, and consolidation across the supply chain. This could impact profitability.

Viatris' global operations are subject to risks including compliance with local laws, regulations, and customs, as well as sanctions, trade controls, and political instability. These risks can impact operations and financial results.

The 10K states that the company faces vigorous competition that threatens the commercial acceptance and pricing of our products. The company faces increasing competition from lower-cost generic products and other branded products.

The 10K states that the use of legal, regulatory, and legislative strategies by both brand and generic competitors, including but not limited to “authorized generics” and regulatory petitions, may increase costs associated with the introduction or marketing of our generic products, could delay or prevent such introduction, and could significantly reduce our revenue and profit.

The 10K states that the Company is further enhancing its commercial and scientific capabilities as needed for this future portfolio and intends to increase its R&D investment as well as inorganically grow via business development through its Global Healthcare Gateway®.

The 10K states that the pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations. Our manufacturing is conducted under exacting conditions governed by extensive regulation including strict in-process and finished pharmaceutical products specifications and controls.

The 10K states that supply disruptions and increases in energy and transportation costs may negatively impact operations. We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process.

The 10K states that we are committed to minimizing our impact on the environment while safeguarding a reliable supply of medicine. Our commitment entails systematic and continuous work, and a global integrated approach to managing our impact on and from climate change, energy efficiency and renewable energy, water and waste reduction, and air emissions.

The 10K states that the Company is further enhancing its commercial and scientific capabilities as needed for this future portfolio and intends to increase its R&D investment as well as inorganically grow via business development through its Global Healthcare Gateway®.

The 10K states that the Company is working on many other programs, including the potential to be first to market for our generics of Abilify Maintena®, Injectafer®, Invega Trinza®, Ozempic®, Venofer® and Wegovym.

The 10K states that the Company is also working with our partners on novel and complex products such as our BOTOX® (onabotulinumtoxinA) biosimilar and Glatiramer Acetate Depot, a long-acting injection version of the approved glatiramer acetate.

The Board of Directors authorized a share repurchase program for up to $2 billion. This indicates a commitment to returning capital to shareholders.

A quarterly cash dividend of $0.12 per share was declared, demonstrating a commitment to returning capital to shareholders.

The company intends to increase its R&D investment as well as inorganically grow via business development through its Global Healthcare Gateway®.

The 10K states that Viatris has company wide sustainability goals in the areas of access; diversity, equity & inclusion; and the environment: climate change, water and waste. Achievement of these goals depends on our development and execution of various operational strategies relating to each discrete target.

The 10K states that as part of having our Scope 1, 2 and 3 emission reduction targets validated and approved by SBTi, SBTi classified Viatris' scope 1 and 2 target ambition and has determined that it is in line with the 1.5°C trajectory.

The 10K states that we remain engaged in promoting environmentally responsible supply chains, including through the continued adoption of the AMR Industry Alliance's Common Antibiotic Manufacturing Standard in our operations and in the external supply chain.

In China, the recent healthcare reform measures are aimed at controlling the overall healthcare costs, while providing better and broader care to the population. Healthcare spending is expected to increase in-line with GDP growth.

In China, pricing pressures have increased in recent years, and the Chinese government has also increased its focus on patient access and reimbursement for pharmaceutical medicines.

The 10K states that healthcare spending is expected to increase in-line with GDP growth. The VBP policy for LOE molecules is now in its fifth year and includes more than 330 molecules. All major Viatris brands are included in the VBP molecule lists.